#BEGIN_DRUGCARD DB04299

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
110-16-7

# ChEBI_ID:
18300

# Chemical_Formula:
C4H4O4

# Chemical_IUPAC_Name:
(2E)-but-2-enedioic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Enzyme Inhibitors

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.48

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
4.41E+005 mg/L (at 25 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Maleic Acid

# HET_ID:
MAE

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C4H4O4/c5-3(6)1-2-4(7)8/h1-2H,(H,5,6)(H,7,8)/b2-1+

# InChI_Key:
InChIKey=VZCYOOQTPOCHFL-OWOJBTEDSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
C01384

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
4299

# Mechanism_Of_Action:
Not Available

# Melting_Point:
130.5 °C

# Molecular_Weight_Avg:
116.0722

# Molecular_Weight_Mono:
116.010958616

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1K7H

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
0.21

# Predicted_LogS:
-0.68

# Predicted_Water_Solubility:
2.41e+01 g/l

# Primary_Accession_No:
DB04299

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
444972

# PubChem_Substance_ID:
46508977

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02106

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC(=O)\C=C\C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:23:11 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
1.83

# Drug_Target_1_Cellular_Location:
Cytoplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
GOT1

# Drug_Target_1_GenBank_ID_Gene:
M37400

# Drug_Target_1_GenBank_ID_Protein:
179067

# Drug_Target_1_GeneCard_ID:
GOT1

# Drug_Target_1_Gene_Name:
GOT1

# Drug_Target_1_Gene_Sequence:
>1242 bp
ATGGCACCTCCGTCAGTCTTTGCCGAGGTTCCGCAGGCCCAGCCTGTCCTGGTCTTCAAG
CTCACTGCCGACTTCAGGGAGGATCCGGACCCCCGCAAGGTCAACCTGGGAGTGGGAGCA
TATCGCACGGATGACTGCCATCCCTGGGTTTTGCCAGTAGTGAAGAAAGTGGAGCAGAAG
ATTGCTAATGACAATAGCCTAAATCACGAGTATCTGCCAATCCTGGGCCTGGCTGAGTTC
CGGAGCTGTGCTTCTCGTCTTGCCCTTGGGGATGACAGCCCAGCACTCAAGGAGAAGCGG
GTAGGAGGTGTGCAATCTTTGGGGGGAACAGGTGCACTTCGAATTGGAGCTGATTTCTTA
GCGCGTTGGTACAATGGAACAAACAACAAGAACACACCTGTCTATGTGTCCTCACCAACC
TGGGAGAATCACAATGCTGTGTTTTCCGCTGCTGGTTTTAAAGACATTCGGTCCTATCGC
TACTGGGATGCAGAGAAGAGAGGATTGGACCTCCAGGGCTTCCTGAATGATCTGGAGAAT
GCTCCTGAGTTCTCCATTGTTGTCCTCCACGCCTGTGCACACAACCCAACTGGGATTGAC
CCAACTCCGGAGCAGTGGAAGCAGATTGCTTCTGTCATGAAGCACCGGTTTCTGTTCCCC
TTCTTTGACTCAGCCTATCAGGGCTTCGCATCTGGAAACCTGGAGAGAGATGCCTGGGCC
ATTCGCTATTTTGTGTCTGAAGGCTTCGAGTTCTTCTGTGCCCAGTCCTTCTCCAAGAAC
TTCGGGCTCTACAATGAGAGAGTCGGGAATCTGACTGTGGTTGGAAAAGAACCTGAGAGC
ATCCTGCAAGTCCTTTCCCAGATGGAGAAGATCGTGCGGATTACTTGGTCCAATCCCCCC
GCCCAGGGAGCACGAATTGTGGCCAGCACCCTCTCTAACCCTGAGCTCTTTGAGGAATGG
ACAGGTAATGTGAAGACAATGGCTGACCGGATTCTGACCATGAGATCTGAACTCAGGGCA
CGACTAGAAGCCCTCAAAACCCCTGGGACCTGGAACCACATCACTGATCAAATTGGCATG
TTCAGCTTCACTGGGTTGAACCCCAAGCAGGTTGAGTATCTGGTCAATGAAAAGCACATC
TACCTGCTGCCAAGTGGTCGAATCAACGTGAGTGGCTTAACCACCAAAAATCTAGATTAC
GTGGCCACCTCCATCCATGAAGCAGTCACCAAAATCCAGTGA

# Drug_Target_1_General_Function:
Amino acid transport and metabolism

# Drug_Target_1_General_References:
1974457	Bousquet-Lemercier B, Pol S, Pave-Preux M, Hanoune J, Barouki R: Properties of human liver cytosolic aspartate aminotransferase mRNAs generated by alternative polyadenylation site selection. Biochemistry. 1990 Jun 5;29(22):5293-9.
2241899	Doyle JM, Schinina ME, Bossa F, Doonan S: The amino acid sequence of cytosolic aspartate aminotransferase from human liver. Biochem J. 1990 Sep 15;270(3):651-7.

# Drug_Target_1_HGNC_ID:
HGNC:4432

# Drug_Target_1_HPRD_ID:
00687

# Drug_Target_1_ID:
586

# Drug_Target_1_Locus:
10q24.1-q25.1

# Drug_Target_1_Molecular_Weight:
46117

# Drug_Target_1_Name:
Aspartate aminotransferase, cytoplasmic

# Drug_Target_1_Number_of_Residues:
412

# Drug_Target_1_PDB_ID:
1AJS

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00155	Aminotran_1_2

# Drug_Target_1_Protein_Sequence:
>Aspartate aminotransferase, cytoplasmic
APPSVFAEVPQAQPVLVFKLTADFREDPDPRKVNLGVGAYRTDDCHPWVLPVVKKVEQKI
ANDNSLNHEYLPILGLAEFRSCASRLALGDDSPALKEKRVGGVQSLGGTGALRIGADFLA
RWYNGTNNKNTPVYVSSPTWENHNAVFSAAGFKDIRSYRYWDAEKRGLDLQGFLNDLENA
PEFSIVVLHACAHNPTGIDPTPEQWKQIASVMKHRFLFPFFDSAYQGFASGNLERDAWAI
RYFVSEGFEFFCAQSFSKNFGLYNERVGNLTVVGKEPESILQVLSQMEKIVRITWSNPPA
QGARIVASTLSNPELFEEWTGNVKTMADRILTMRSELRARLEALKTPGTWNHITDQIGMF
SFTGLNPKQVEYLVNEKHIYLLPSGRINVSGLTTKNLDYVATSIHEAVTKIQ

# Drug_Target_1_Reaction:
L-aspartate + 2-oxoglutarate = oxaloacetate + L-glutamate

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
P17174

# Drug_Target_1_SwissProt_Name:
AATC_HUMAN

# Drug_Target_1_Synonyms:
EC 2.6.1.1
Glutamate oxaloacetate transaminase 1
Transaminase A

# Drug_Target_1_Theoretical_pI:
7.01

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasm

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
X03629

# Drug_Target_2_GenBank_ID_Protein:
41011

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
aspC

# Drug_Target_2_Gene_Sequence:
>1191 bp
ATGTTTGAGAACATTACCGCCGCTCCTGCCGACCCGATTCTGGGCCTGGCCGATCTGTTT
CGTGCCGATGAACGTCCCGGCAAAATTAACCTCGGGATTGGTGTCTATAAAGATGAGACG
GGCAAAACCCCGGTACTGACCAGCGTGAAAAAGGCTGAACAGTATCTGCTCGAAAATGAA
ACCACCAAAAATTACCTCGGCATTGACGGCATCCCTGAATTTGGTCGCTGCACTCAGGAA
CTGCTGTTTGGTAAAGGTAGCGCCCTGATCAATGACAAACGTGCTCGCACGGCACAGACT
CCGGGGGGCACTGGCGCACTACGCGTGGCTGCCGATTTCCTGGCAAAAAATACCAGCGTT
AAGCGTGTGTGGGTGAGCAACCCAAGCTGGCCGAACCATAAGAGCGTCTTTAACTCTGCA
GGTCTGGAAGTTCGTGAATACGCTTATTATGATGCGGAAAATCACACTCTTGACTTCGAT
GCACTGATTAACAGCCTGAATGAAGCTCAGGCTGGCGACGTAGTGCTGTTCCATGGCTGC
TGCCATAACCCAACCGGTATCGACCCTACGCTGGAACAATGGCAAACACTGGCACAACTC
TCCGTTGAGAAAGGCTGGTTACCGCTGTTTGACTTCGCTTACCAGGGTTTTGCCCGTGGT
CTGGAAGAAGATGCTGAAGGACTGCGCGCTTTCGCGGCTATGCATAAAGAGCTGATTGTT
GCCAGTTCCTACTCTAAAAACTTTGGCCTGTACAACGAGCGTGTTGGCGCTTGTACTCTG
GTTGCTGCCGACAGTGAAACCGTTGATCGCGCATTCAGCCAAATGAAAGCGGCGATTCGC
GCTAACTACTCTAACCCACCAGCACACGGCGCTTCTGTTGTTGCCACCATCCTGAGCAAC
GATGCGTTACGTGCGATTTGGGAACAAGAGCTGACTGATATGCGCCAGCGTATTCAGCGT
ATGCGTCAGTTGTTCGTCAATACGCTGCAGGAAAAAGGCGCAAACCGCGACTTCAGCTTT
ATCATCAAACAGAACGGCATGTTCTCCTTCAGTGGCCTGACAAAAGAACAAGTGCTGCGT
CTGCGCGAAGAGTTTGGCGTATATGCGGTTGCTTCTGGTCGCGTAAATGTGGCCGGGATG
ACACCAGATAACATGGCTCCGCTGTGCGAAGCGATTGTGGCAGTGCTGTAA

# Drug_Target_2_General_Function:
Amino acid transport and metabolism

# Drug_Target_2_General_References:
1868057	Inoue K, Kuramitsu S, Okamoto A, Hirotsu K, Higuchi T, Kagamiyama H: Site-directed mutagenesis of Escherichia coli aspartate aminotransferase: role of Tyr70 in the catalytic processes. Biochemistry. 1991 Aug 6;30(31):7796-801.
1993208	Danishefsky AT, Onnufer JJ, Petsko GA, Ringe D: Activity and structure of the active-site mutants R386Y and R386F of Escherichia coli aspartate aminotransferase. Biochemistry. 1991 Feb 19;30(7):1980-5.
2007566	Yano T, Kuramitsu S, Tanase S, Morino Y, Hiromi K, Kagamiyama H: The role of His143 in the catalytic mechanism of Escherichia coli aspartate aminotransferase. J Biol Chem. 1991 Apr 5;266(10):6079-85.
2513875	Smith DL, Almo SC, Toney MD, Ringe D: 2.8-A-resolution crystal structure of an active-site mutant of aspartate aminotransferase from Escherichia coli. Biochemistry. 1989 Oct 3;28(20):8161-7.
3298240	Kondo K, Wakabayashi S, Kagamiyama H: Structural studies on aspartate aminotransferase from Escherichia coli. Covalent structure. J Biol Chem. 1987 Jun 25;262(18):8648-57.
3521591	Fotheringham IG, Dacey SA, Taylor PP, Smith TJ, Hunter MG, Finlay ME, Primrose SB, Parker DM, Edwards RM: The cloning and sequence analysis of the aspC and tyrB genes from Escherichia coli K12. Comparison of the primary structures of the aspartate aminotransferase and aromatic aminotransferase of E. coli with those of the pig aspartate aminotransferase isoenzymes. Biochem J. 1986 Mar 15;234(3):593-604.
3897210	Kuramitsu S, Okuno S, Ogawa T, Ogawa H, Kagamiyama H: Aspartate aminotransferase of Escherichia coli: nucleotide sequence of the aspC gene. J Biochem (Tokyo). 1985 Apr;97(4):1259-62.
6378205	Kondo K, Wakabayashi S, Yagi T, Kagamiyama H: The complete amino acid sequence of aspartate aminotransferase from Escherichia coli: sequence comparison with pig isoenzymes. Biochem Biophys Res Commun. 1984 Jul 18;122(1):62-7.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9298646	Link AJ, Robison K, Church GM: Comparing the predicted and observed properties of proteins encoded in the genome of Escherichia coli K-12. Electrophoresis. 1997 Aug;18(8):1259-313.
9891001	Oue S, Okamoto A, Yano T, Kagamiyama H: Redesigning the substrate specificity of an enzyme by cumulative effects of the mutations of non-active site residues. J Biol Chem. 1999 Jan 22;274(4):2344-9.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
2249

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
43574

# Drug_Target_2_Name:
Aspartate aminotransferase

# Drug_Target_2_Number_of_Residues:
396

# Drug_Target_2_PDB_ID:
1CQ8

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00155	Aminotran_1_2

# Drug_Target_2_Protein_Sequence:
>Aspartate aminotransferase
MFENITAAPADPILGLADLFRADERPGKINLGIGVYKDETGKTPVLTSVKKAEQYLLENE
TTKNYLGIDGIPEFGRCTQELLFGKGSALINDKRARTAQTPGGTGALRVAADFLAKNTSV
KRVWVSNPSWPNHKSVFNSAGLEVREYAYYDAENHTLDFDALINSLNEAQAGDVVLFHGC
CHNPTGIDPTLEQWQTLAQLSVEKGWLPLFDFAYQGFARGLEEDAEGLRAFAAMHKELIV
ASSYSKNFGLYNERVGACTLVAADSETVDRAFSQMKAAIRANYSNPPAHGASVVATILSN
DALRAIWEQELTDMRQRIQRMRQLFVNTLQEKGANRDFSFIIKQNGMFSFSGLTKEQVLR
LREEFGVYAVASGRVNVAGMTPDNMAPLCEAIVAVL

# Drug_Target_2_Reaction:
L-aspartate + 2-oxoglutarate = oxaloacetate + L-glutamate

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
L-aspartate + 2-oxoglutarate = oxaloacetate + L-glutamate

# Drug_Target_2_SwissProt_ID:
P00509

# Drug_Target_2_SwissProt_Name:
AAT_ECOLI

# Drug_Target_2_Synonyms:
ASPAT
EC 2.6.1.1
Transaminase A

# Drug_Target_2_Theoretical_pI:
5.50

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cytoplasm

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
M38051

# Drug_Target_3_GenBank_ID_Protein:
162317

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
TPR

# Drug_Target_3_Gene_Sequence:
>1479 bp
ATGATGTCAAAAATTTTTGATTTGGTTGTCATTGGCGCCGGCTCGGGCGGACTGGAGGCT
GCTTGGAACGCGGCGACACTCTACAAGAAGCGGGTTGCGGTGATTGATGTTCAGATGGTT
CACGGGCCCCCGTTTTTTTCTGCTCTAGGCGGCACGTGTGTCAATGTTGGCTGCGTTCCG
AAGAAATTGATGGTTACAGGGGCCCAATACATGGAACACCTGCGCGAGTCCGCTGGGTTC
GGGTGGGAGTTTGATCGCACCACTCTCAGGGCGGAATGGAAGAAACTTATTGCTGTCAAG
GACGAGGCGGTGCTGAATATCAACAAGAGTTATGAGGAGATGTTTCGGGACACGGAGGGT
CTGGAGTTTTTTCTGGGCTGGGGATCACTGGAGTCAAAGAATGTCGTCAATGTTCGCGAG
AGTGCCGACCCGGCCAGCGCAGTGAAGGAGCGCCTGGAGACGGAGAACATTCTACTTGCC
AGTGGTTCGTGGCCGCACATGCCAAACATCCCTGGTATTGAGCATTGCATCAGCAGCAAT
GAGGCATTTTACCTGCCGGAGCCACCGCGTCGTGTCCTCACTGTCGGCGGAGGTTTCATT
TCCGTGGAGTTCGCCGGCATTTTTAACGCCTACAAGCCGAAAGACGGACAAGTGACGTTG
TGCTACCGCGGTGAAATGATCCTTCGTGGCTTTGACCACACTCTCCGTGAGGAACTCACA
AAGCAGCTCACCGCCAACGGCATTCAAATCCTTACAAAGGAAAATCCGGCCAAGGTGGAG
TTGAACGCGGATGGCAGCAAAAGTGTTACTTTCGAGAGCGGCAAAAAGATGGACTTTGAT
CTTGTCATGATGGCGATTGGCCGTTCTCCCCGAACAAAGGATTTACAGCTGCAAAACGCC
GGCGTCATGATCAAGAACGGTGGTGTGCAGGTGGACGAGTACTCGCGCACGAATGTTTCC
AACATTTACGCCATCGGTGACGTCACAAATCGTGTCATGTTGACACCCGTTGCCATAAAT
GAAGCCGCTGCCCTTGTGGATACCGTCTTTGGTACCAATCCGCGAAAGACGGACCACACC
CGTGTGGCGAGTGCCGTCTTCTCTATTCCTCCAATTGGTACCTGCGGTCTCATTGAAGAG
GTTGCATCCAAGCGCTACGAGGTGGTGGCGGTATACCTTTCCAGCTTTACCCCGCTCATG
CACAACATCAGCGGATCAAAGTATAAGACTTTTGTTGCAAAGATAATTACCAACCACTCC
GATGGCACTGTGCTTGGTGTACATCTTCTTGGGGACAATGCCCCAGAAATCATCCAAGGT
GTTGGTATCTGTCTCAAGTTAAATGCCAAAATATCCGACTTCTACAACACTATTGGTGTG
CATCCCACAAGTGCGGAGGAGCTGTGCTCCATGCGCACTCCTTCTTACTACTATGTTAAA
GGTGAGAAGATGGAAAAGCCTTCAGAGGCATCTCTGTAA

# Drug_Target_3_General_Function:
Energy production and conversion

# Drug_Target_3_General_References:
2011150	Sullivan FX, Walsh CT: Cloning, sequencing, overproduction and purification of trypanothione reductase from Trypanosoma cruzi. Mol Biochem Parasitol. 1991 Jan;44(1):145-7.
7737173	Borges A, Cunningham ML, Tovar J, Fairlamb AH: Site-directed mutagenesis of the redox-active cysteines of Trypanosoma cruzi trypanothione reductase. Eur J Biochem. 1995 Mar 15;228(3):745-52.
8159665	Lantwin CB, Schlichting I, Kabsch W, Pai EF, Krauth-Siegel RL: The structure of Trypanosoma cruzi trypanothione reductase in the oxidized and NADPH reduced state. Proteins. 1994 Feb;18(2):161-73.
8771196	Zhang Y, Bond CS, Bailey S, Cunningham ML, Fairlamb AH, Hunter WN: The crystal structure of trypanothione reductase from the human pathogen Trypanosoma cruzi at 2.3 A resolution. Protein Sci. 1996 Jan;5(1):52-61.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
2823

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
53868

# Drug_Target_3_Name:
Trypanothione reductase

# Drug_Target_3_Number_of_Residues:
492

# Drug_Target_3_PDB_ID:
1NDA

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00070	Pyr_redox
PF02852	Pyr_redox_dim
PF07992	Pyr_redox_2

# Drug_Target_3_Protein_Sequence:
>Trypanothione reductase
MMSKIFDLVVIGAGSGGLEAAWNAATLYKKRVAVIDVQMVHGPPFFSALGGTCVNVGCVP
KKLMVTGAQYMEHLRESAGFGWEFDRTTLRAEWKKLIAVKDEAVLNINKSYEEMFRDTEG
LEFFLGWGSLESKNVVNVRESADPASAVKERLETENILLASGSWPHMPNIPGIEHCISSN
EAFYLPEPPRRVLTVGGGFISVEFAGIFNAYKPKDGQVTLCYRGEMILRGFDHTLREELT
KQLTANGIQILTKENPAKVELNADGSKSVTFESGKKMDFDLVMMAIGRSPRTKDLQLQNA
GVMIKNGGVQVDEYSRTNVSNIYAIGDVTNRVMLTPVAINEAAALVDTVFGTNPRKTDHT
RVASAVFSIPPIGTCGLIEEVASKRYEVVAVYLSSFTPLMHNISGSKYKTFVAKIITNHS
DGTVLGVHLLGDNAPEIIQGVGICLKLNAKISDFYNTIGVHPTSAEELCSMRTPSYYYVK
GEKMEKPSEASL

# Drug_Target_3_Reaction:
trypanothione + NADP+ = trypanothione disulfide + NADPH + H+

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Trypanothione is the parasite analog of glutathione; this enzyme is the equivalent of glutathione reductase

# Drug_Target_3_SwissProt_ID:
P28593

# Drug_Target_3_SwissProt_Name:
TYTR_TRYCR

# Drug_Target_3_Synonyms:
EC 1.8.1.12
N(1),N(8)- bis(glutathionyl)spermidine reductase
TR

# Drug_Target_3_Theoretical_pI:
6.68

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Cytoplasm

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
D38459

# Drug_Target_4_GenBank_ID_Protein:
1255699

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
aspC

# Drug_Target_4_Gene_Sequence:
>1158 bp
ATGCGCGGCCTTTCCCGAAGGGTCCAGGCCATGAAGCCCTCGGCCACGGTGGCGGTGAAC
GCCAAGGCCCTGGAGCTCAGGCGCCAAGGGGTGGACCTCGTGGCCCTCACCGCCGGCGAG
CCCGACTTTGACACCCCCGAGCACGTGAAGGAGGCGGCGAGGCGCGCCCTCGCCCAGGGG
AAGACCAAGTACGCCCCCCCTGCGGGGATCCCCGAGCTTCGGGAGGCCCTGGCGGAGAAG
TTCCGCCGGGAAAACGGCCTCTCCGTGACCCCTGAGGAGACCATCGTCACCGTGGGGGGG
AAGCAGGCCCTCTTCAACCTCTTCCAGGCCATCCTGGACCCGGGGGACGAGGTCATCGTC
CTGAGCCCCTACTGGGTGAGCTACCCGGAGATGGTGCGCTTCGCCGGGGGGGTGGTGGTG
GAGGTGGAAACCCTCCCCGAGGAAGGCTTCGTCCCCGACCCCGAGAGGGTCCGGCGGGCC
ATCACCCCCCGCACCAAGGCCCTTGTGGTCAACTCCCCCAACAACCCCACGGGGGCGGTC
TACCCGAAGGAGGTCCTCGAGGCCCTGGCGAGGCTTGCGGTGGAGCACGACTTCTACCTG
GTCTCCGACGAGATCTACGAGCACCTCCTCTACGAGGGGGAGCACTTCTCCCCTGGGCGC
GTGGCCCCCGAGCACACCCTCACGGTGAACGGGGCGGCCAAGGCCTTCGCCATGACCGGA
TGGCGCATCGGCTACGCCTGCGGGCCCAAGGAGGTCATCAAGGCCATGGCCTCCGTCTCC
AGCCAGTCCACCACGAGCCCCGACACCATCGCCCAGTGGGCCACCCTGGAGGCCCTCACC
AACCAGGAGGCCTCCCGCGCCTTCGTGGAGATGGCCAGGGAGGCCTACCGCAGGAGGCGG
GACCTGTTGCTTGAGGGCCTTACCGCCCTGGGCCTCAAGGCGGTGCGCCCGAGCGGGGCC
TTCTACGTCCTCATGGACACCTCCCCCATCGCCCCCGACGAGGTGCGGGCGGCGGAGAGG
CTCCTTGAGGCGGGGGTGGCGGTGGTCCCGGGCACGGACTTCGCCGCCTTCGGCCACGTC
CGCCTCTCCTACGCCACCAGCGAGGAGAACCTCAGGAAGGCCCTGGAGCGCTTCGCCCGG
GTGCTGGGGCGCGCCTAG

# Drug_Target_4_General_Function:
Amino acid transport and metabolism

# Drug_Target_4_General_References:
10029535	Nakai T, Okada K, Akutsu S, Miyahara I, Kawaguchi S, Kato R, Kuramitsu S, Hirotsu K: Structure of Thermus thermophilus HB8 aspartate aminotransferase and its complex with maleate. Biochemistry. 1999 Feb 23;38(8):2413-24.
8907187	Okamoto A, Kato R, Masui R, Yamagishi A, Oshima T, Kuramitsu S: An aspartate aminotransferase from an extremely thermophilic bacterium, Thermus thermophilus HB8. J Biochem (Tokyo). 1996 Jan;119(1):135-44.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
2671

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
42051

# Drug_Target_4_Name:
Aspartate aminotransferase

# Drug_Target_4_Number_of_Residues:
385

# Drug_Target_4_PDB_ID:
1BKG

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00155	Aminotran_1_2

# Drug_Target_4_Protein_Sequence:
>Aspartate aminotransferase
MRGLSRRVQAMKPSATVAVNAKALELRRQGVDLVALTAGEPDFDTPEHVKEAARRALAQG
KTKYAPPAGIPELREALAEKFRRENGLSVTPEETIVTVGGKQALFNLFQAILDPGDEVIV
LSPYWVSYPEMVRFAGGVVVEVETLPEEGFVPDPERVRRAITPRTKALVVNSPNNPTGAV
YPKEVLEALARLAVEHDFYLVSDEIYEHLLYEGEHFSPGRVAPEHTLTVNGAAKAFAMTG
WRIGYACGPKEVIKAMASVSSQSTTSPDTIAQWATLEALTNQEASRAFVEMAREAYRRRR
DLLLEGLTALGLKAVRPSGAFYVLMDTSPIAPDEVRAAERLLEAGVAVVPGTDFAAFGHV
RLSYATSEENLRKALERFARVLGRA

# Drug_Target_4_Reaction:
L-aspartate + 2-oxoglutarate = oxaloacetate + L-glutamate

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
L-aspartate + 2-oxoglutarate = oxaloacetate + L-glutamate

# Drug_Target_4_SwissProt_ID:
Q56232

# Drug_Target_4_SwissProt_Name:
AAT_THET8

# Drug_Target_4_Synonyms:
ASPAT
EC 2.6.1.1
Transaminase A

# Drug_Target_4_Theoretical_pI:
6.29

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Cytoplasm

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
Y08272

# Drug_Target_5_GenBank_ID_Protein:
1806263

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
tyrB

# Drug_Target_5_Gene_Sequence:
>1185 bp
ATGCTGGGCAATCTGAAACCGCAGGCCCCCGACAAGATCCTGGCCCTGATGGGCGAATTC
AGGGCCGATCCCCGCCAGGGCAAGATCGACCTGGGCGTGGGGGTCTACAAGGATGCCACC
GGCCACACCCCGATCATGCGGGCCGTCCACGCCGCCGAGCAGCGCATGCTGGAAACCGAG
ACCACCAAGACCTATGCCGGCCTCTCGGGCGAGCCCGAGTTCCAAAAGGCCATGGGCGAG
CTGATCCTGGGCGACGGACTGAAATCCGAGACCACCGCGACGCTGGCGACGGTCGGCGGC
ACCGGCGCCCTCCGGCAGGCGCTGGAACTGGCGCGCATGGCGAACCCGGACCTGCGGGTC
TTCGTCAGCGATCCGACCTGGCCGAACCATGTCTCGATCATGAATTTCATGGGCCTGCCG
GTGCAGACCTATCGCTATTTCGATGCCGAGACCCGCGGCGTCGATTTCGAGGGCATGAAG
GCCGACCTCGCCGCCGCGAAAAAGGGCGACATGGTGCTGCTGCACGGCTGCTGCCACAAC
CCGACCGGCGCCAACCTGACGCTGGATCAATGGGCCGAGATCGCCTCGATCCTGGAAAAG
ACCGGCGCGCTGCCGCTGATCGACCTGGCCTATCAGGGCTTCGGCGACGGGCTGGAAGAG
GACGCGGCCGGCACCCGGCTGATCGCCTCGCGCATCCCCGAGGTGCTGATCGCGGCCTCG
TGCAGCAAGAACTTCGGCATCTACCGCGAACGCACCGGCTGCCTGCTGGCGCTTTGCGCC
GATGCGGCGACCAGGGAGCTGGCGCAGGGCGCCATGGCCTTCCTGAACCGCCAGACCTAT
TCCTTCCCGCCCTTCCACGGCGCCAAGATCGTCTCGACCGTGCTGACCACGCCCGAACTG
CGCGCCGACTGGATGGCCGAGCTGGAAGCGGTGCGCAGCGGCATGCTGCGCCTGCGCGAG
CAATTGGCGGGCGAGTTGCGCGATCTCAGCGGTTCGGACCGTTTCGGCTTCGTGGCCGAG
CATCGCGGCATGTTCTCGCGCCTGGGCGCCACGCCCGAACAGGTCAAGCGCATCAAGGAA
GAGTTCGGCATCTACATGGTGGGCGATTCGCGCATCAACATCGCCGGGCTGAACGACAAC
ACCATCCCGATCCTGGCCCGCGCTATCATCGAGGTGGGGGTCTAA

# Drug_Target_5_General_Function:
Amino acid transport and metabolism

# Drug_Target_5_General_References:
9058208	Oue S, Okamoto A, Nakai Y, Nakahira M, Shibatani T, Hayashi H, Kagamiyama H: Paracoccus denitrificans aromatic amino acid aminotransferase: a model enzyme for the study of dual substrate recognition mechanism. J Biochem (Tokyo). 1997 Jan;121(1):161-71.
9665848	Okamoto A, Nakai Y, Hayashi H, Hirotsu K, Kagamiyama H: Crystal structures of Paracoccus denitrificans aromatic amino acid aminotransferase: a substrate recognition site constructed by rearrangement of hydrogen bond network. J Mol Biol. 1998 Jul 17;280(3):443-61.
9930977	Okamoto A, Ishii S, Hirotsu K, Kagamiyama H: The active site of Paracoccus denitrificans aromatic amino acid aminotransferase has contrary properties: flexibility and rigidity. Biochemistry. 1999 Jan 26;38(4):1176-84.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
2537

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
42733

# Drug_Target_5_Name:
Aromatic-amino-acid aminotransferase

# Drug_Target_5_Number_of_Residues:
394

# Drug_Target_5_PDB_ID:
2AY7

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00155	Aminotran_1_2

# Drug_Target_5_Protein_Sequence:
>Aromatic-amino-acid aminotransferase
MLGNLKPQAPDKILALMGEFRADPRQGKIDLGVGVYKDATGHTPIMRAVHAAEQRMLETE
TTKTYAGLSGEPEFQKAMGELILGDGLKSETTATLATVGGTGALRQALELARMANPDLRV
FVSDPTWPNHVSIMNFMGLPVQTYRYFDAETRGVDFEGMKADLAAAKKGDMVLLHGCCHN
PTGANLTLDQWAEIASILEKTGALPLIDLAYQGFGDGLEEDAAGTRLIASRIPEVLIAAS
CSKNFGIYRERTGCLLALCADAATRELAQGAMAFLNRQTYSFPPFHGAKIVSTVLTTPEL
RADWMAELEAVRSGMLRLREQLAGELRDLSGSDRFGFVAEHRGMFSRLGATPEQVKRIKE
EFGIYMVGDSRINIAGLNDNTIPILARAIIEVGV

# Drug_Target_5_Reaction:
an aromatic amino acid + 2-oxoglutarate = an aromatic oxo acid + L-glutamate

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Shows activities toward both dicarboxylic and aromatic substrates

# Drug_Target_5_SwissProt_ID:
P95468

# Drug_Target_5_SwissProt_Name:
TYRB_PARDE

# Drug_Target_5_Synonyms:
ARAT
AROAT
EC 2.6.1.57

# Drug_Target_5_Theoretical_pI:
5.49

# Drug_Target_5_Transmembrane_Regions:
None

#END_DRUGCARD DB04299
